News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karo Bio AB Announces That Merck & Co., Inc. (MRK) Discontinues Development of Mk-6913 for Hot Flashes



9/8/2010 12:01:49 PM

Sep 08, 2010 (NORDIC BUSINESS REPORT via COMTEX) --8 September 2010 - Swedish drug developer Karo Bio AB (STO: KARO) has been notified by its US partner Merck & Co Inc (NYSE: MRK | PowerRating) that it decided to discontinue the development of their joint drug candidate MK-6913 for the treatment of hot flashes.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES